1. Home
  2. LEA vs TGTX Comparison

LEA vs TGTX Comparison

Compare LEA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lear Corporation

LEA

Lear Corporation

N/A

Current Price

$128.05

Market Cap

8.3B

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$56.26

Market Cap

7.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LEA
TGTX
Founded
1917
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
7.9B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
LEA
TGTX
Price
$128.05
$56.26
Analyst Decision
Buy
Strong Buy
Analyst Count
14
5
Target Price
$132.21
$49.80
AVG Volume (30 Days)
509.8K
1.8M
Earning Date
05-01-2026
05-04-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
1746.67
EPS
7.13
0.17
Revenue
$23,259,100,000.00
$2,785,000.00
Revenue This Year
$2.50
$49.08
Revenue Next Year
$3.12
$26.69
P/E Ratio
$17.70
$312.00
Revenue Growth
N/A
N/A
52 Week Low
$96.04
$26.76
52 Week High
$150.33
$59.30

Technical Indicators

Market Signals
Indicator
LEA
TGTX
Relative Strength Index (RSI) 46.56 46.99
Support Level $116.08 $51.51
Resistance Level $128.04 $58.12
Average True Range (ATR) 3.05 2.07
MACD 0.48 -0.28
Stochastic Oscillator 31.96 14.62

Price Performance

Historical Comparison
LEA
TGTX

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: